Drugs / PAN-301-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03120832 | Dec 2016 → Dec 2018 | prostate cancer | Sensei Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAN-301-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03120832 ↗ |
| Modality | Vaccine | “PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine” NCT03120832 ↗ |